Real-world insights on membranous nephropathy treatments for adults and children
Official title: Real-world Comparative Treatment Effectiveness and Surrogate Outcome Evaluation in Membranous Nephropathy using Observational Data
Funded at Children's Hosp of Philadelphia · NIH-11365444 · Data updated 2026-11-12
This grant tests how different real-world treatments for membranous nephropathy perform over time using observational health data.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Children's Hosp of Philadelphia NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | May 15, 2026 |
| Project end | February 28, 2031 |
| Funding year | 2026 |
| Award (this year) | $949,759 |
| NIH project number | 1R01DK144396-01A1 |
| Project ID | NIH-11365444 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults and children with membranous nephropathy who have received or are considering immunosuppressive treatments.
✕Less likely to help
Patients with membranous nephropathy not represented in the included cohorts or those not using immunosuppressive therapy may see limited relevance.
What this research studies
Membranous nephropathy is a serious kidney disease that can affect both adults and children. The project uses modern methods to compare long-term outcomes and safety of available treatments by analyzing data from large patient groups over many years. It also looks at a biomarker, PLA2R antibodies, to see if it can predict long-term outcomes and serve as a surrogate endpoint for future trials. Data will come from established patient cohorts and electronic health records to emulate what a clinical trial would show in the real world.
Why it matters
Potential benefit: If successful, patients could receive better, data-driven treatment guidance that improves long-term kidney outcomes and safety.
How similar studies have gone: Previous observational studies and causal-inference work have advanced understanding in real-world treatment effects for MN, with ongoing efforts to validate biomarkers.
Where this research is happening
-
Children's Hosp of Philadelphia
Philadelphia, United States Active
Researchers
- Principal investigator: Zee, Jarcy — Children's Hosp of Philadelphia
- Study coordinator: Zee, Jarcy
Related research
Other NIH-funded projects on the same topics.
-
Investigating how lipoic acid affects autoimmune kidney disease.
This study is looking at how the dietary supplement lipoic acid might affect people with membranous nephropathy, a kidney disease, by seeing if it triggers immune responses that could lead to complications, so we can better spot and treat those at risk.
-
Investigating the role of HTRA1 in causing kidney disease
This study is looking at how certain antibodies in people with primary membranous nephropathy (a kidney condition) affect the disease and aims to find better ways to diagnose and treat it, using new animal models to learn more about how the disease works.
-
Identifying harmful T cells in patients with membranous nephropathy.
This study is looking at how certain immune cells called T cells behave in people with membranous nephropathy, a kidney disease, to help find better ways to understand and treat the condition.
-
Understanding how autoantibodies affect kidney function in membranous nephropathy
This study is looking at how certain antibodies in the body affect kidney health in people with primary membranous nephropathy, with the hope of finding better ways to treat the disease and help patients feel better.
-
Rituximab plus Cyclosporine for Primary Membranous Nephropathy
This study tests whether adding Cyclosporine to Rituximab helps people with primary membranous nephropathy achieve remission of heavy protein in the urine faster.
-
HLX79 with rituximab (HLX01) for active glomerulonephritis
This trial will test whether adding HLX79 at different doses to rituximab (HLX01) helps adults with active membranous nephropathy or lupus nephritis.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.